Investigation of Chromosome 1 Aberrations in the Lymphocytes of Prostate Cancer and Benign Prostatic Hyperplasia Patients by Fluorescence in situ Hybridization

References

• Beskid O, Binkova B, Dusek Z, et al. Chromosomal aberrations by fluorescence in situ hybridization (FISH) - Biomarker of exposure to carcinogenic PAHs. Mutat Res. 2007;690:62–70. doi:10.1016/j.mrfmmm.2007.02.023
   Web of Science ®Google Scholar
• Bonassi S. Chromosomal aberration in peripheral blood lymphocytes of healthy subjects and risk of cancer. In: Vijayalaxmi OG, editor. Chromosomal Alterations. Berlin, Heidelberg: Springer; 2007.
   Google Scholar
• Cebulska-Wasilewska A. Response to challenging dose of X-rays as a predictive assay for molecular epidemiology. Mutat Res. 2003;544:289–297. doi:10.1016/j.mrrev.2003.07.00314644330
   PubMed Web of Science ®Google Scholar
• Grade M, Difilippantonio MJ, Camps J. Patterns of chromosomal aberrations in solid tumors. Recent Results Cancer Res. 2015;200:115–142.26376875
   PubMedGoogle Scholar
• Boei JJ, Vermeulen S, Natarajan AT. Detection of chromosomal aberrations by fluorescence in situ hybridization in the first three post-irradiation divisions of human lymphocytes. Mutat Res. 1996;349:127–135. doi:10.1016/0027-5107(95)00171-98569785
   PubMed Web of Science ®Google Scholar
• Rana S, Kumar R, Sultana S, Sharma RK. Radiation-induced biomarkers for the detection and assessment of absorbed radiation doses. J Pharm Bioallied Sci. 2010;2(3):189–196. doi:10.4103/0975-7406.6850021829314
   PubMedGoogle Scholar
• Mladenov E, Magin S, Soni A, Iliakis G. DNA double-strand break repair as determinant of cellular radiosensitivity to killing and target in radiation therapy. Front Oncol. 2013;3:113. doi:10.3389/fonc.2013.0011323675572
   PubMedGoogle Scholar
• Grönberg H. Prostate cancer epidemiology. Lancet. 2003;361:859–864. doi:10.1016/S0140-6736(03)12713-412642065
   PubMed Web of Science ®Google Scholar
• Chughtai B, Forde JC, Thomas DDM, et al. Benign prostatic hyperplasia. Nature Rev. 2016;16032.
   Google Scholar
• Mirone V, Fusco F, Verze P, et al. Androgens and benign prostatic hyperplasia. Eur Urol Supp. 2006;5:410–417. doi:10.1016/j.eursup.2006.02.004
   Web of Science ®Google Scholar
• Rakel D. Chapter 60 - Benign prostatic hyperplasia. In: Integrative Medicine. Elsevier, 4th; 2018:601–607. doi:10.1016/B978-0-323-35868-2.00060-8
   Google Scholar
• Gallardo FF, Quintar AA. The pathological growth of the prostate gland in atherogenic contexts. Exp Gerontol. 2021;148:111304. doi:10.1016/j.exger.2021.11130433676974
   PubMed Web of Science ®Google Scholar
• Singh R, Eeles RA, Durocher F, et al. High risk genes predisposing to prostate cancer development – do they exist? Prostate Cancer Prostatic Dis. 2000;3:241–247. doi:10.1038/sj.pcan.450047812497071
   PubMed Web of Science ®Google Scholar
• Frank C, Sundquist J, Hemminki A, Hemminki K. Familial associations between prostate cancer and other cancers. Eur Urol. 2017;71:162–165. doi:10.1016/j.eururo.2016.07.03127498599
   PubMed Web of Science ®Google Scholar
• Ballon-Landa E, Parsons JK. Nutrition, physical activity, and lifestyle factors in prostate cancer prevention. Curr Opin Urol. 2018;28:55–61. doi:10.1097/MOU.000000000000046029049045
   PubMed Web of Science ®Google Scholar
• Saramäki OR, Visakorpi T. Chromosomal aberrations in prostate cancer. Front Biosci. 2018;12:3287–3301. doi:10.2741/2312
   Web of Science ®Google Scholar
• Smith JR, Freije D, Carpten JD, et al. Major susceptibility locus for prostate cancer on chromosome 1 suggested by a genome-wide search. Science. 1996;274:1371–1374. doi:10.1126/science.274.5291.13718910276
   PubMed Web of Science ®Google Scholar
• Robinson D, Garmo H, Lissbrant IF, et al. Prostate cancer death after radiotherapy or radical prostatectomy: a nationwide population-based observational study. Eur Urol. 2018;73:502–511. doi:10.1016/j.eururo.2017.11.03929254629
   PubMed Web of Science ®Google Scholar
• Podder TK, Fredman ET, Ellis RJ. Advances in radiotherapy for prostate cancer treatment. Adv Exp Med Biol. 2018;1096:31–47.
   PubMedGoogle Scholar
• Takakusagi Y, Hiroyuki Katoh H, Kano K. Preliminary result of carbon-ion radiotherapy using the spot scanning method for prostate cancer. Radiat Oncol. 2020;15:127. doi:10.1186/s13014-020-01575-732460889
   PubMed Web of Science ®Google Scholar
• Cytogenetic dosimetry: applications in preparedness for and response to radiation emergencies, IAEA report. Vienna; 2011.
   Google Scholar
• Cebulska-Wasilewska A, Miszczyk J, Balegenowa N, et al. Studies of the susceptibility to radiation of prostate cancer or BPH patients and healthy donors. In: Cebulska-Wasilewska A, Osipov AN, Darroudi F, editors. Rapid Diagnosis in Populations at Risk from Radiation and Chemicals. Vol. 73. IOS Press Amsterdam; 2010:211–220. ISBN 978-1-60750-644-7.
   Google Scholar
• Prasanna PGS, Hamel CJC, Escalada ND, et al. Biological dosimetry using human interphase peripheral blood lymphocytes. Mil Med. 2002;167:10–12. doi:10.1093/milmed/167.suppl_1.10
   PubMedGoogle Scholar
• Fowler JF. The radiobiology of prostate cancer including new aspects of fractionated radiotherapy. Acta Oncol. 2005;44(3):265–276. doi:10.1080/0284186041000282416076699
   PubMed Web of Science ®Google Scholar
• Hille A, Hofman-Hüther H, Kühnle E, et al. Spontaneous and radiation-induced chromosomal instability and persistence of chromosome aberrations after radiotherapy in lymphocytes from prostate cancer patients. Radiat Environ Biophys. 2010;49:27–37. doi:10.1007/s00411-009-0244-x19760427
   PubMed Web of Science ®Google Scholar
• Beaton LA, Marro L, Samiee S, et al. Investigating chromosome damage using fluorescent in situ hybridization to identify biomarkers of radiosensitivity in prostate cancer patients. Int J Radiat Biol. 2013;89:1087–1093. doi:10.3109/09553002.2013.82506023855681
   PubMed Web of Science ®Google Scholar
• Beaton LA, Ferrarotto C, Marro L, et al. Chromosome damage and cell proliferation rates in vitro irradiated whole blood as markers of late radiation toxicity after the radiation therapy to the prostate. Int J Radiat Oncol Biol Phys. 2013;85:1346–1352. doi:10.1016/j.ijrobp.2012.09.02623158059
   PubMed Web of Science ®Google Scholar
• El-Zein R, Gu Y, Sierra MS, et al. Chromosomal instability in peripheral blood lymphocytes and risk of prostate cancer. Cancer Epidemiol Biomarkers Prev. 2005;14:748–752. doi:10.1158/1055-9965.EPI-04-023615767363
   PubMed Web of Science ®Google Scholar
• Xu J, Zheng SL, Chang B, et al. Linkage of prostate cancer susceptibility loci to chromosome 1. Hum Genet. 2001;189:335–345. doi:10.1007/s004390100488
   Web of Science ®Google Scholar
• Berthon P, Valeri A, Cohen-Akenine A, et al. Predisposing gene for early-onset prostate cancer, localized on chromosome 1q42.2-43. Am J Hum Genet. 1998:1416–1424.9585607
   PubMed Web of Science ®Google Scholar
• Miszczyk J, Cebulska-Wasilewska A. Retrospective biological dosimetry of the absorbed dose – training on the estimation of the radiation dose of a person presumably exposed to X-ray radiation by FISH. In: Cebulska-Wasilewska A, Osipov AN, Darroudi F, editors. Rapid Diagnosis in Populations at Risk from Radiation and Chemicals. Vol. 73. IOS Press Amsterdam. 2010;211–220. ISBN 978-1-60750-644-7.
   Google Scholar
• Miszczyk J, Cebulska-Wasilewska A, Glazar B, et al. Comparison between susceptibilities to radiation treatment of lymphocytes from prostate cancer (PC) with BPH patients. Eur Urol Suppl. 2012;11(4):126–127. doi:10.1016/S1569-9056(13)60184-0
   Google Scholar
• Vodenkova S, Polivkova Z, Musak L, et al. Structural chromosomal aberrations as potential risk markers in incident cancer patients. Mutagenesis. 2015;30:557–563. doi:10.1093/mutage/gev01825800034
   PubMed Web of Science ®Google Scholar
• Distel LVR, Neubauer S, Keller U, et al. Individual differences in chromosomal aberrations after in vitro irradiation of cells from healthy individuals, cancer and cancer susceptibility syndrome patients. Radiat Oncol. 2006;81:257–263. doi:10.1016/j.radonc.2006.10.012
   Web of Science ®Google Scholar
• Wilson JD, Hammond EM, Higgins GS, Petersson K. Ultra-high dose rate (FLASH) radiotherapy: silver bullet or fool’s gold? Front Oncol. 2020;9:1563. doi:10.3389/fonc.2019.0156332010633
   PubMed Web of Science ®Google Scholar
• Miszczyk J, Rawojć K, Panek A, et al. Do protons and X-rays induce cell-killing in human peripheral blood lymphocytes by different mechanisms? Clin Transl Radiat Oncol. 2018;31(9):23–29. doi:10.1016/j.ctro.2018.01.004
   Web of Science ®Google Scholar
• Kaddour A, Colicchio B, Buron D, et al. Transmission of induced chromosomal aberrations through successive mitotic divisions in human lymphocytes after in vitro and in vivo radiation. Sci Rep. 2017;7(1):3291. doi:10.1038/s41598-017-03198-728607452
   PubMed Web of Science ®Google Scholar